Sectors
The medical device producer has now raised $40m in financing altogether, having secured $4m in a Novo-backed equity round and $4m in debt from GE Capital.
All three of the biotechnology company's corporate backers, Johnson & Johnson, Eli Lilly and Pharmstandard, returned for its latest round, and it has now raised $67m in total.
McKesson and Independence Health provided the capital for healthcare marketplace Accolade, which previously received funding from investors including Comcast.
Oncology-focused biotechnology developer Immunocore has raised the largest ever funding round by a European private life sciences company.
The asthma and peanut allergy treatment company has now raised $89m in total, after closing a series D round backed by BioMed Realty and returning investor Novo.
Merck Global Health Innovation Fund co-led the $5m equity portion of the series B round, while Silicon Valley Bank provided $3m in debt financing.
Nuvelution, which is aiming to bring a collaborative element to drug development, has raised an undisclosed amount in a Novo-backed series A round.
The healthcare research services provider will contribute $50m of the capital as an anchor investor and seek to fund China and US-based portfolio companies.
The GlaxoSmithKline spin-out, which is working on treatments for hearing disorders, has raised additional funds to extend the Pfizer-backed round to $36.6m.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
